SMLR1: A Drug Target / Disease Biomarker (G100507203)

Target Name: SMLR1

NCBI ID: G100507203

SMLR1

Other Name(s): Small leucine-rich protein 1 | small leucine rich protein 1 | FLJ34581 | Small leucine rich protein 1 | SMLR1_HUMAN

SMLR1: A Drug Target / Disease Biomarker

SMLR1 (Sudkimib) is a drug target and potential biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SMLR1 is a small molecule that is expressed in various tissues and cells in the body. It is a heat-labile protein and has a molecular weight of approximately 11 kDa. SMLR1 is a G protein-coupled receptor (GPCR), which means it is a transmembrane protein that is involved in intracellular signaling.

SMLR1 is involved in a wide range of physiological processes in the body, including cell survival, growth, and angiogenesis (the formation of new blood vessels). It is a negative regulator of the RhoA GPCR, which is a well-known signaling pathway that is involved in cell proliferation, migration, and invasion. SMLR1 functions as an antagonist of RhoA, which means it inhibits the activity of RhoA and reduces the formation of new blood vessels.

SMLR1 has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of SMLR1 are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, high levels of SMLR1 have been shown to be associated with the development of cancer, including breast cancer and lung cancer.

SMLR1 has also been shown to be involved in the regulation of cellular processes that are important for cell survival and angiogenesis. For example, studies have shown that SMLR1 plays a role in the regulation of cell apoptosis (programmed cell death), which is a natural process that helps maintain the integrity of tissues and organs. Additionally, SMLR1 has been shown to be involved in the regulation of cell proliferation, which is important for the growth and development of tissues and organs.

SMLR1 has also been shown to be involved in the regulation of cellular signaling pathways that are important for cell survival and angiogenesis. For example, studies have shown that SMLR1 is involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the formation of new blood vessels. Additionally, SMLR1 is involved in the regulation of the TGF-β signaling pathway, which is involved in cell proliferation and angiogenesis.

In conclusion, SMLR1 is a drug target and potential biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SMLR1 is involved in a wide range of physiological processes in the body, including cell survival, growth, and angiogenesis. It is a negative regulator of the RhoA GPCR and has been shown to be involved in the development and progression of various diseases. Further research is needed to fully understand the role of SMLR1 in the treatment of these diseases.

Protein Name: Small Leucine Rich Protein 1

The "SMLR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMLR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets